Causes and timing of recurring subarctic Pacific hypoxia.

Several North Pacific studies of the last deglaciation show hypoxia throughout the ocean margins and attribute this phenomenon to the effects of abrupt warming and meltwater inputs. Yet, because of the lack of long records spanning multiple glacial cycles and deglaciation events, it is unclear whether deoxygenation was a regular occurrence of warming events and whether deglaciation and/or other conditions promoted hypoxia throughout time. Here, subarctic Pacific laminated sediments from the past 1.2 million years demonstrate that hypoxic events recurred throughout the Pleistocene as episodes of highly productive phytoplankton growth and were generally associated with interglacial climates, high sea levels, and enhanced nitrate utilization-but not with deglaciations. We suggest that hypoxia was typically stimulated by high productivity from iron fertilization facilitated by redox-remobilized iron from flooded continental shelves.

Clinical Signs, Treatment, and Outcome in Cats with Myeloma-Related Disorder Receiving Systemic Therapy.

Myeloma-related disorder (MRD) is an uncommon disease in cats, for which there is no established standard of care. In this retrospective study, we evaluated presentation, response to treatment, and toxicity in cats with MRD receiving systemic treatment. Previously reported prognostic factors were evaluated for their impact on survival in cats receiving chemotherapy. Of fifteen cases identified, thirteen received melphalan or cyclophosphamide +/- corticosteroids as first-line therapy. Chlorambucil was commonly used as rescue therapy in cats with progressive disease, or in cases of chemotherapy-related toxicity with first line agents. Overall response rates were 71% and 83% for melphalan- and cyclophosphamide-treated cats, respectively. Discontinuation of melphalan due to toxicity was common. Survival times for cats initially treated with melphalan or cyclophosphamide were not significantly different (median 252 and 394 days, respectively), and no statistically significant prognostic factors were identified. This study suggests that the combination of cyclophosphamide and corticosteroids is well tolerated and may be considered as first-line therapy for cats with systemic MRD.

Safety of ultrasound-guided fine-needle aspiration of the feline pancreas: a case-control study.

The safety of fine-needle aspiration (FNA) of the feline pancreas has not been reported. The incidence of complications following ultrasound-guided pancreatic FNA in 73 cats (pancreatic aspirate [PA] cats) with clinical and ultrasonographic evidence of pancreatic disease was compared with complications in two groups of matched control cats also diagnosed with pancreatic disease that either had abdominal organs other than the pancreas aspirated (control FNA, n = 63) or no aspirates performed (control no FNA, n = 61). The complication rate within 48 h of the ultrasound and/or aspirate procedure did not differ among the PA cats (11%), control FNA (14%) or control no FNA (8%) cats. There was no difference in rate of survival to discharge (82%, 84% and 83%, respectively) or length of hospital stay among groups. The cytologic recovery rate for the pancreatic samples was 67%. Correlation with histopathology, available in seven cases, was 86%. Pancreatic FNA in cats is a safe procedure requiring further investigation to establish diagnostic value.